<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00691392</url>
  </required_header>
  <id_info>
    <org_study_id>TBTC Study 30PK</org_study_id>
    <nct_id>NCT00691392</nct_id>
  </id_info>
  <brief_title>Linezolid Pharmacokinetics (PK) in Multi-Drug Resistant (MDR)/Extensively-Drug Resistant (XDR) Tuberculosis (TB)</brief_title>
  <acronym>S30PK</acronym>
  <official_title>Linezolid Pharmacokinetics and Pharmacodynamics in the Treatment of Multi-Drug Resistant and Extensively-Drug Resistant Tuberculosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centers for Disease Control and Prevention</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Texas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of KwaZulu</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Cape Town</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Boston University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Centers for Disease Control and Prevention</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a one-period, double-blind, single-center pharmacokinetic study of linezolid in
      patients with MDR or XDR tuberculosis treated with linezolid and an Optimized Background
      Therapy (defined as treatment with &gt; 4 drugs with activity against tuberculosis to which the
      patient's isolate is believed to be sensitive by history or based on drug sensitivity
      testing).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a one-period, double-blind, single-center pharmacokinetic study of linezolid in
      patients with MDR or XDR tuberculosis treated with linezolid and an Optimized Background
      Therapy (defined as treatment with &gt; 4 drugs with activity against tuberculosis to which the
      patient's isolate is believed to be sensitive by history or based on drug sensitivity
      testing).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Characterize linezolid pharmacokinetic parameters (AUC0-24 and linezolid time over MIC) in patients with MDR-TB and XDR-TB.</measure>
    <time_frame>1 month after the start of study therapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess the pharmacodynamic effects of linezolid AUC0-24 on tolerability (bone marrow toxicity, peripheral and ocular neuropathies) and safety during four months of treatment of tuberculosis</measure>
    <time_frame>20 weeks after starting study therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>characterize the pharmacokinetics of ofloxacin and potentially other second line anti-tuberculous drugs utilized in the treatment of patients with MDR TB.</measure>
    <time_frame>one month after starting study therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the pharmacodynamic effect of linezolid pharmacokinetic parameters ( on biomarkers of treatment activity. Biomarkers to be evaluated are time to detection in liquid culture, sputum culture conversion at two and four months of study treatment.</measure>
    <time_frame>16 weeks after starting study therapy</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Multi-Drug Resistant Tuberculosis</condition>
  <condition>Extensively Drug Resistant Tuberculosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Linezolid 600 mg po daily for 16 weeks (112 doses) given in addition to optimized background therapy for MDR TB</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Over-encapsulated microcrystalline methylcellulose (Avicel) - an inert filler</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Linezolid</intervention_name>
    <description>Linezolid 600 mg po daily for 16 weeks (112 doses) - over-encapsulated</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Zyvox</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Microcrystalline Methylcellulose - Placebo</intervention_name>
    <description>The placebo will be over-encapsulated microcrystalline methylcellulose</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Avicel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Enrolled in the TBTC Study 30

          -  Provision of informed consent for the study

        Exclusion Criteria:

          -  Severe anemia as defined by a hematocrit less than 25% (most recent value, measured
             within 30 days of the PK study).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nesri Padayatchi, MBChB</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of KwaZulu</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marc Weiner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas at San Antonio</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>King George V Hospital</name>
      <address>
        <city>Durban</city>
        <state>KwaZulu Natal</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>South Africa</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 3, 2008</study_first_submitted>
  <study_first_submitted_qc>June 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2008</study_first_posted>
  <last_update_submitted>August 15, 2012</last_update_submitted>
  <last_update_submitted_qc>August 15, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 17, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multi-Drug Resistant Tuberculosis</keyword>
  <keyword>Extensively Drug Resistant Tuberculosis</keyword>
  <keyword>MDR TB</keyword>
  <keyword>XDR TB</keyword>
  <keyword>MDR</keyword>
  <keyword>XDR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Tuberculosis, Multidrug-Resistant</mesh_term>
    <mesh_term>Extensively Drug-Resistant Tuberculosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Linezolid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

